BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.33B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 2.25M
Average 2.04M
BMRN EBITDA Margin
EBITDA as a percentage of revenue.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin narrows to -8.0%
EBITDA Margin was -8.0% in Q3 FY2026, down 7.3 pp from a year earlier. On a trailing-twelve-month basis it was -8.0%, down 32.9 pp year over year. Over 3 fiscal years it widened by 5.1 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 20 analysts of 21.2% for the fiscal year ending Dec 2026, up from 17.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -8.0%-30.5 pp QoQ
- Last fiscal yearDec 2025
- 17.8%-5.0 pp YoY
- LTMSep 2026
- -8.0%-32.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.3 pp | +33.6 pp | +40.9 pp |
| 1 year | -5.0 pp | +3.4 pp | +8.4 pp |
| 3 years | +5.1 pp | +21.9 pp | +16.7 pp |
| 5 years | +25.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 17.8%
- Year-over-year change
- -5.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.8% | -5.0pp |
| FY2024 | 2024-12-31 | 22.8% | +10.1pp |
| FY2023 | 2023-12-31 | 12.7% | +0.0pp |
| FY2022 | 2022-12-31 | 12.7% | +10.1pp |
| FY2021 | 2021-12-31 | 2.6% | — |
EBITDA Margin vs competitors
How BMRN compares with its peers on the latest reported figures
- BMRN's LTM Sep 2026 EBITDA Margin of -8.0% is the 6th highest of the 11 companies compared; the peer median is -2.8%.
- Its year-over-year change of -32.9 pp is the 10th highest of 11, against a peer median of +2.5 pp.
- Over three fiscal years its change of +5.1 pp compares with a peer median of +104.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Sep 2026 | 37.4% | -2.3 pp | -9.4 pp | |
| LTM Jun 2026 | 24.0% | +30.9 pp | +106.3 pp | |
| LTM Sep 2026 | 21.5% | +42.1 pp | +1018.2 pp | |
| LTM Jun 2026 | 17.2% | -30.5 pp | +103.9 pp | |
| LTM Mar 2026 | 10.7% | +3.9 pp | -7.9 pp | |
| LTM Sep 2026 | -8.0% | -32.9 pp | +5.1 pp | |
| LTM Sep 2026 | -16.4% | -11.2 pp | +278.1 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Jun 2026 | -67.8% | +167.9 pp | -10.9 pp | |
| LTM Mar 2026 | -75.2% | +1.0 pp | +105.9 pp | |
| LTM Jun 2026 | -85.7% | +187.2 pp | +377.1 pp | |
| Peer median (excluding BMRN) | -2.8% | +2.5 pp | +104.9 pp | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.85B | 2.1B | 2.42B | 2.85B | 3.22B |
| Cost of Revenue | 470.52M | 503.02M | 532.06M | 580.24M | 736.83M |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.48B |
| Gross Margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.1% |
| Research & Development | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Selling, General & Admin | 759.4M | 823.2M | 892.4M | 1.01B | 1.28B |
| Operating Expenses | 1.46B | 1.43B | 1.7B | 1.79B | 1.95B |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| EBITDA | 47.43M | 265.36M | 306.77M | 650.53M | 572.94M |
| EBITDA Margin | 2.6% | 12.7% | 12.7% | 22.8% | 17.8% |
| Operating Income | (82.34M) | 160.97M | 185.77M | 484.21M | 533.48M |
| Operating Margin | -4.5% | 7.7% | 7.7% | 17.0% | 16.6% |
| Interest Income | 10.48M | 18.03M | 58.34M | 74.88M | 74.9M |
| Interest Expense | 15.34M | 15.97M | 17.34M | 12.67M | 10.9M |
| Other Income / Expenses | 6.99M | (11.4M) | 2.79M | 57.55M | (51M) |
| Income Before Tax | (75.35M) | 149.58M | 188.56M | 541.76M | 482.48M |
| Pre-Tax Margin | -4.1% | 7.1% | 7.8% | 19.0% | 15.0% |
| Income Tax Expense | (11.27M) | 8.02M | 20.92M | 114.9M | 133.58M |
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Net Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% |
| EPS (Basic) | (0.35) | 0.76 | 0.89 | 2.25 | 1.82 |
| EPS (Diluted) | (0.35) | 0.75 | 0.88 | 2.21 | 1.80 |
| Weighted Avg Shares | 182.85M | 185.27M | 187.83M | 190.03M | 191.79M |
| Weighted Avg Shares (Diluted) | 182.85M | 188.96M | 191.6M | 196.71M | 197.39M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$58.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.